Cargando…
Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study
OBJECTIVE: To estimate benefits and harms of different colorectal cancer screening strategies, stratified by (baseline) 15-year colorectal cancer risk. DESIGN: Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon). SETTING: A parallel guideline committee (BMJ...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774435/ https://www.ncbi.nlm.nih.gov/pubmed/31578177 http://dx.doi.org/10.1136/bmj.l5383 |
_version_ | 1783456079641837568 |
---|---|
author | Buskermolen, Maaike Cenin, Dayna R Helsingen, Lise M Guyatt, Gordon Vandvik, Per Olav Haug, Ulrike Bretthauer, Michael Lansdorp-Vogelaar, Iris |
author_facet | Buskermolen, Maaike Cenin, Dayna R Helsingen, Lise M Guyatt, Gordon Vandvik, Per Olav Haug, Ulrike Bretthauer, Michael Lansdorp-Vogelaar, Iris |
author_sort | Buskermolen, Maaike |
collection | PubMed |
description | OBJECTIVE: To estimate benefits and harms of different colorectal cancer screening strategies, stratified by (baseline) 15-year colorectal cancer risk. DESIGN: Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon). SETTING: A parallel guideline committee (BMJ Rapid Recommendations) defined the time frame and screening interventions, including selection of outcome measures. POPULATION: Norwegian men and women aged 50-79 years with varying 15-year colorectal cancer risk (1-7%). COMPARISONS: Four screening strategies were compared with no screening: biennial or annual faecal immunochemical test (FIT) or single sigmoidoscopy or colonoscopy at 100% adherence. MAIN OUTCOME MEASURES: Colorectal cancer mortality and incidence, burdens, and harms over 15 years of follow-up. The certainty of the evidence was assessed using the GRADE approach. RESULTS: Over 15 years of follow-up, screening individuals aged 50-79 at 3% risk of colorectal cancer with annual FIT or single colonoscopy reduced colorectal cancer mortality by 6 per 1000 individuals. Single sigmoidoscopy and biennial FIT reduced it by 5 per 1000 individuals. Colonoscopy, sigmoidoscopy, and annual FIT reduced colorectal cancer incidence by 10, 8, and 4 per 1000 individuals, respectively. The estimated incidence reduction for biennial FIT was 1 per 1000 individuals. Serious harms were estimated to be between 3 per 1000 (biennial FIT) and 5 per 1000 individuals (colonoscopy); harms increased with older age. The absolute benefits of screening increased with increasing colorectal cancer risk, while harms were less affected by baseline risk. Results were sensitive to the setting defined by the guideline panel. Because of uncertainty associated with modelling assumptions, we applied a GRADE rating of low certainty evidence to all estimates. CONCLUSIONS: Over a 15 year period, all screening strategies may reduce colorectal cancer mortality to a similar extent. Colonoscopy and sigmoidoscopy may also reduce colorectal cancer incidence, while FIT shows a smaller incidence reduction. Harms are rare and of similar magnitude for all screening strategies. |
format | Online Article Text |
id | pubmed-6774435 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67744352019-10-21 Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study Buskermolen, Maaike Cenin, Dayna R Helsingen, Lise M Guyatt, Gordon Vandvik, Per Olav Haug, Ulrike Bretthauer, Michael Lansdorp-Vogelaar, Iris BMJ Research OBJECTIVE: To estimate benefits and harms of different colorectal cancer screening strategies, stratified by (baseline) 15-year colorectal cancer risk. DESIGN: Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon). SETTING: A parallel guideline committee (BMJ Rapid Recommendations) defined the time frame and screening interventions, including selection of outcome measures. POPULATION: Norwegian men and women aged 50-79 years with varying 15-year colorectal cancer risk (1-7%). COMPARISONS: Four screening strategies were compared with no screening: biennial or annual faecal immunochemical test (FIT) or single sigmoidoscopy or colonoscopy at 100% adherence. MAIN OUTCOME MEASURES: Colorectal cancer mortality and incidence, burdens, and harms over 15 years of follow-up. The certainty of the evidence was assessed using the GRADE approach. RESULTS: Over 15 years of follow-up, screening individuals aged 50-79 at 3% risk of colorectal cancer with annual FIT or single colonoscopy reduced colorectal cancer mortality by 6 per 1000 individuals. Single sigmoidoscopy and biennial FIT reduced it by 5 per 1000 individuals. Colonoscopy, sigmoidoscopy, and annual FIT reduced colorectal cancer incidence by 10, 8, and 4 per 1000 individuals, respectively. The estimated incidence reduction for biennial FIT was 1 per 1000 individuals. Serious harms were estimated to be between 3 per 1000 (biennial FIT) and 5 per 1000 individuals (colonoscopy); harms increased with older age. The absolute benefits of screening increased with increasing colorectal cancer risk, while harms were less affected by baseline risk. Results were sensitive to the setting defined by the guideline panel. Because of uncertainty associated with modelling assumptions, we applied a GRADE rating of low certainty evidence to all estimates. CONCLUSIONS: Over a 15 year period, all screening strategies may reduce colorectal cancer mortality to a similar extent. Colonoscopy and sigmoidoscopy may also reduce colorectal cancer incidence, while FIT shows a smaller incidence reduction. Harms are rare and of similar magnitude for all screening strategies. BMJ Publishing Group Ltd. 2019-10-02 /pmc/articles/PMC6774435/ /pubmed/31578177 http://dx.doi.org/10.1136/bmj.l5383 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Research Buskermolen, Maaike Cenin, Dayna R Helsingen, Lise M Guyatt, Gordon Vandvik, Per Olav Haug, Ulrike Bretthauer, Michael Lansdorp-Vogelaar, Iris Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study |
title | Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study |
title_full | Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study |
title_fullStr | Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study |
title_full_unstemmed | Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study |
title_short | Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study |
title_sort | colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774435/ https://www.ncbi.nlm.nih.gov/pubmed/31578177 http://dx.doi.org/10.1136/bmj.l5383 |
work_keys_str_mv | AT buskermolenmaaike colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy AT cenindaynar colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy AT helsingenlisem colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy AT guyattgordon colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy AT vandvikperolav colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy AT haugulrike colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy AT bretthauermichael colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy AT lansdorpvogelaariris colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy |